Adherence to Biochemical Monitoring Recommendations in Patients Starting with Renin Angiotensin System Inhibitors
- First Online:
- 48 Downloads
Background: Renin angiotensin system inhibitors (RASIs) are frequently involved in serious adverse events. These events principally occur in high-risk patients and often arise within the first days after treatment initiation; therefore, guidelines recommend biochemical monitoring within 3 weeks after the start of therapy with RASIs.
Objective: The purpose of this study was to examine the level of biochemical monitoring directly after treatment initiation with RASIs in patients with different risk profiles and to study the attitudes of the physicians involved towards biochemical monitoring.
Methods: We carried out a retrospective analysis of 202 patients who started RASI therapy in 2006 in Groesbeek, the Netherlands. We determined the rate of serum creatinine and potassium monitoring within 3 weeks after the start of therapy. In addition, we studied the intentions and attitudes towards biochemical monitoring during RASI therapy among 68 general practitioners and medical specialists by way of a brief questionnaire.
Results: Serum creatinine and potassium monitoring after treatment initiation was performed in 34% and 28% of patients, respectively. Of all the patients, 29% had two or more additional risk factors for renal function deterioration. In these high-risk patients, creatinine was significantly less often monitored compared with low-risk patients (22% vs 39%). In contrast to these findings, the prescribing physicians claimed to check serum creatinine within 2 weeks after treatment initiation in 85% of their patients. Most of the prescribing physicians (88%) rated this monitoring as (very) important.
Conclusions: We demonstrated that, despite positive intentions of physicians, the biochemical monitoring recommendation in patients treated with RASIs is poorly met. In addition, serum creatinine monitoring was significantly less often performed in high-risk patients compared with low-risk patients.
- 1.College voor zorgverzekeringen (CVZ). GIPdatabank. Aantal gebruikers 2004–2008 voor ATC-subgroep C09 [online]. Available from URL: www.gipdatabank.nl/index.asp [Accessed 2011 Mar 14]
- 6.Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327(10): 669–77PubMedCrossRefGoogle Scholar
- 8.Maschio G, Alberti D, Janin G, et al. Effect of the angiotensinconverting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334(15): 939–45PubMedCrossRefGoogle Scholar
- 14.Ministerie van Volksgezondheid, Welzijn en Sport (VWS). Expert Group Medicatieveiligheid. Hospital admissions related to medication wrestling rapport [online]. Available from URL: http://www.rijksoverheid.nl/documenten-en-publicaties/rapporten/2008/02/25/rapport-expertgroep-medicatieveiligheid.html [Accessed 2011 Mar 14]
- 19.Centraal Begeleidings Orgaan (CBO). Multidisciplinaire richtlijn: cardiovasculair risicomanagement, 2006 [online]. Available from URL: www.cbo.nl/Downloads/217/rl_cvrm_2006.pdf [Accessed 2011 Mar 14]
- 20.Nederlands Huisartsen Genootschap (NHG). NHG standaard hartfalen, 2005 [online]. Available from URL: www.nhg.artsennet.nl/kenniscentrum/k_richtlijnen/k_nhgstandaarden/Samenvattingskaartje-NHGStandaard/M51_svk.htm [Accessed 2011 Mar 14]
- 21.Walma EP, Thomas S, Prins A, et al. NHG-standaard hypertensie. Huisarts Wet 2003; 46(8): 435–49Google Scholar
- 22.Nederlands Huisartsen Genootschap (NHG). NHG standard diabetes mellitus type 2, 2006 [online]. Available from URL: www.nhg.artsennet.nl/kenniscentrum/k_richtlijnen/k_nhgstandaarden/Samenvattingskaartje-NHGStandaard/M01_svk.htm [Accessed 2011 Mar 14]
- 23.Nederlandse Internisten Vereniging (NIV). NIV richtlijn Diabetische nefropathie, 2006 [online]. Available from URL: www.internisten.nl/uploads/tK/kz/tKkzFNAqWOd0lannj7M_sg/5-richtlijndiabetischenefropathiesamenvattingenadviezen.pdf [Accessed 2011 Mar 14]
- 24.Nederlandse Vereniging voor Cardiologie (NVVC). Richtlijnen voor de diagnose en behandeling van chronisch hartfalen [online]. Available from URL: www.nvvc.nl/UserFiles/Richtlijnen/NVVC/Richtlijnen%20voor%20de%20diagnose%20en%20behandeling%20van%20chronisch%20hartfalen%202005.pdf [Accessed 2011 Mar 14]
- 25.Scottish Intercollegiate Guidelines Network (SIGN). Management of chronic heart failure: a national clinical guideline [online]. Available from URL: www.sign.ac.uk/pdf/sign95.pdf [Accessed 2011 Mar 14]
- 26.National Collaborating Centre for Chronic Conditions. Chronic heart failure [online]. Available from URL: www.nice.org.uk/nicemedia/live/13099/50517/50517.pdf [Accessed 2011 Mar 14]
- 27.National Collaborating Centre for Chronic Conditions. Post myocardial infarction: secondary prevention in primary and secondary care for patients following a myocardial infarction [online]. Available from URL: www.nice.org.uk/nicemedia/live/11008/30495/30495.pdf [Accessed 2011 Mar 14]
- 28.Kaplan NM, Rose BD. Major side effects of angiotensin converting enzyme inhibitors and angiotensine II receptor blockers [online]. Available from URL: http://www.uptodate.com.proxy.ubn.ru.nl:8080/contents/major-side-effects-of-angiotensin-converting-enzyme-inhibitors-and-angiotensin-ii-receptor-blockers?source=search_result&selectedTitle=1%7E150 [Accessed 2011 Mar 14]
- 29.Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112(12): e154–235PubMedCrossRefGoogle Scholar
- 31.Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26(11): 1115–40PubMedCrossRefGoogle Scholar
- 32.Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008; 10(10): 933–89PubMedCrossRefGoogle Scholar
- 33.National Kidney Foundation (NKF). Clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease [online]. Available from URL: www.kidney.org/Professionals/kdoqi/guidelines_bp/guide_11.htm [Accessed 2011 Mar 14]
- 45.Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch Intern Med 1998; 158(1): 26–32Google Scholar